Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$75.68 USD
-1.26 (-1.64%)
Updated May 8, 2024 04:00 PM ET
After-Market: $75.71 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AXSM 75.68 -1.26(-1.64%)
Will AXSM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXSM
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Other News for AXSM
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics price target lowered by $3 at Mizuho, here's why
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials